Q-Med AB: Invitation to Q3 report conference call

Time: Thursday, October 27, 2005 at 11.00 a.m. CET. To join the conference: Swedish dial in number: +46 (0) 8 505 201 10 Danish dial in number: +45 3271 4607 UK dial in number: +44 (0)2071 620 025 Password: Q-Med AB Q-Med participants: Bengt Ågerup, CEO Erika Kjellberg Eriksson, CFO Anne Rhenman, Director Investor Relations and Corporate Communications The press release for Q-Med AB’s Q3 report will be issued around 08.30 CET October 27. The slide presentation will be available at www.q-med.com/Investors/Presentations A recorded version of the presentation will be available for five working days on tel: Sweden +46 (0)8 505 203 33, access code: 67 82 61 or UK +44 (0)20 7031 4064, access code: 67 82 61. Queries should be addressed to: Anne Rhenman, Director Investor Relations and Corporate Communications, Tel: + 46 (0) 70-974 90 15 NASHA, DUROLANE, ZUIDEX, IMPLACER, DEFLUX and all the products within the RESTYLANE family are trademarks that belong to Q-Med. In the US, Q-Med AB´s affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc. Q-Med AB (publ) Seminariegatan 21, SE-752 28 Uppsala, Sweden Corporate identity number 556258-6882 Tel: +46(0) 18-474 90 00 Fax: +46(0) 18-474 90 01 info@q-med.com www.q-med.com

About Us

Q-Med is a rapidly growing and profitable biotechnology and medical device company that develops, produces and markets medical implants. Operations focus on four areas, Esthetics, Orthopedics, Uro-Gynecology, and Cell Therapy and Encapsulation.

Subscribe

Documents & Links